Retrocochlear Diseases: Clinical Trials

87 completed, 37 unknown, 25 recruiting, 16 terminated. 85 Not applicable, 36 Phase 2, 12 Phase 1, 7 Phase 3, 5 Early Phase 1.

By phase and status

Phase	Trials	Status
Not applicable	85	Completed 43, Unknown 17, Recruiting 11, Withdrawn 7, Terminated 4, Active not recruiting 1, Enrolling by invitation 1, Not yet recruiting 1
Phase 2	36	Completed 19, Not yet recruiting 5, Terminated 4, Active not recruiting 3, Recruiting 3, Unknown 2
Phase 1	12	Completed 4, Not yet recruiting 3, Recruiting 2, Active not recruiting 1, Suspended 1, Terminated 1
Phase 3	7	Terminated 3, Completed 2, Not yet recruiting 1, Unknown 1
Early Phase 1	5	Completed 2, Recruiting 1, Terminated 1, Unknown 1
Phase 4	5	Completed 2, Withdrawn 2, Terminated 1

Follow Retrocochlear Diseases: new trials by email Literature Review of Retrocochlear Diseases trials Research Report on Retrocochlear Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant Otic neural progenitors, cochlear implantation - Sensorineural Hearing Loss, Presbyacusis	Phase 1 / Phase 2	Not yet recruiting	Rinri Therapeutics	20	2027-09-01	2026-10-01
Role of ChatGPT in Vestibular Schwannoma Management Use of chatGPT for 1 week - Vestibular Schwannoma	Not applicable	Withdrawn	University of Southern California		2027-01-01	2026-01-13
Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2	Phase 1 / Phase 2	Not yet recruiting	Beijing Tiantan Hospital	30	2026-07-31	2026-07-16
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma	Phase 2	Not yet recruiting	Beijing Tiantan Hospital	200	2026-07-18	2026-07-20
Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2	Phase 2	Not yet recruiting	Beijing Tiantan Hospital	20	2026-07-15	2026-07-16
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures Panitumumab-IRDye800 - Meningioma, Glioblastoma	Early Phase 1	Recruiting	Eben Rosenthal	30	2026-07-07	2026-10-16
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II Trineumin - Neurofibromatosis Type II, NF2	Phase 1 / Phase 2	Not yet recruiting	PRG Science & Technology Co., Ltd.	25	2026-07-01	2026-01-23
Measuring Vestibular Organ Function With Weak Alternating Current Stimulation Active transcranial electrical vestibular stimulation (Active EVS), Sham transcranial electrical vestibular stimulation (Sham EVS), Control measurement - Vestibular Disorder, Vestibular Schwannoma	Not applicable	Enrolling by invitation	Aalto University	30	2026-06-08	2026-07-01
Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery Oliceridine, Sufentanil - PONV, Cerebellopontine Angle Tumor	Not applicable	Recruiting	Xuanwu Hospital, Beijing	174	2026-03-25	2026-05-22
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy Vestibular Schwannoma		Enrolling by invitation	Akouos, Inc.	100	2026-03-02	2026-07-16
Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis Auto-captioning Glasses - NF2-related Schwannomatosis	Not applicable	Completed	Massachusetts General Hospital	18	2026-02-19	2026-08-25
3D MRE-Based Evaluation of Vestibular Schwannoma Mechanical Properties and Histological Features Vestibular Schwannoma		Recruiting	Shengjing Hospital	30	2025-09-25	2026-10-16
Vestibular Rehabilitation Protocol in Unilateral Vestibular Schwannoma No Intervention: Observational Cohort, Structured home-based vestibular telerehabilitation program, CE-marked clinical rotatory chair - Vestibular Schwannoma, Vestibular Schwannomas	Not applicable	Recruiting	Albert Torrents Torrero	75	2025-09-01	2026-01-23
Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients Steroids therapy, Placebo - Vestibular Schwannoma, Facial Nerve Paralysis	Phase 3	Not yet recruiting	Beijing Tiantan Hospital	364	2025-09-01	2025-08-12
Quantitative Eye Movement Measurements in Patients with Acute Vestibular Syndrome video-oculography - Acute Vestibular Syndrome, Vertigo	Not applicable	Not yet recruiting	Alexander Tarnutzer	75	2025-07-01	2024-10-31
Mapping of Vestibular Centers Activation Using fMRI in Patients With Vestibular Schwannoma vestibular schwannoma resection - Vestibular Schwannoma, Unilateral Vestibular Deficit	Not applicable	Recruiting	Marketa Bonaventurova	40	2025-06-01	2026-10-22
Early Rehabilitation Using Head Impulse Test for Acute Vestibular Deficit Experimental treatment: Head movements, Sham treatment: only eye movements - Vestibular Schwannoma, Unilateral Vestibular Deficit	Not applicable	Recruiting	Hospices Civils de Lyon	26	2025-05-13	2025-05-16
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound - Central Auditory Processing Disorder, Hearing Impaired (Partially)	Phase 1 / Phase 2	Recruiting	University of Colorado, Denver	344	2025-03-31	2026-04-30
Hearing Aids for Veterans With Functional Hearing Difficulties Communication Counseling, Hearing Aids, Remote Microphones - Auditory Processing Disorder	Not applicable	Recruiting	VA Office of Research and Development	142	2025-03-09	2026-04-20
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma	Phase 1 / Phase 2	Recruiting	Akouos, Inc.	27	2025-01-17	2026-04-06

Showing 20 of 191. Sign in to see all of them.

Narrower conditions

Neuroma, Acoustic (98)  ·  Neurofibromatosis 2 (47)  ·  Vestibular Neuronitis (33)  ·  Auditory Perceptual Disorders (24)  ·  Meningioma (18)  ·  Dizziness (13)  ·  Hearing Loss (13)  ·  Vertigo (11)  ·  Vestibular Diseases (11)  ·  Brain Neoplasms (10)  ·  Ependymoma (10)  ·  Vestibulocochlear Nerve Diseases (10)  ·  Hearing Loss, Sensorineural (9)  ·  Neurilemmoma (8)  ·  Neurofibromatoses (8)

Broader conditions

Ear Diseases (190)  ·  Nervous System Diseases (190)  ·  Otorhinolaryngologic Diseases (189)  ·  Cranial Nerve Diseases (161)  ·  Vestibulocochlear Nerve Diseases (151)  ·  Cranial Nerve Neoplasms (122)  ·  Neoplasms by Histologic Type (122)  ·  Neoplasms, Nerve Tissue (122)  ·  Nerve Sheath Neoplasms (122)  ·  Neuroectodermal Tumors (122)  ·  Neuroendocrine Tumors (122)  ·  Otorhinolaryngologic Neoplasms (122)  ·  Neoplasms, Germ Cell and Embryonal (121)  ·  Neuroma (121)

Interventions

Bevacizumab (7)  ·  Radiosurgery (6)  ·  Cochlear Implants (4)  ·  Everolimus (4)  ·  AZD 6244 (3)  ·  Gentamicins (3)  ·  Hearing Aids (3)  ·  Adrenal Cortex Hormones (2)  ·  Ginkgo Extract (2)  ·  HDAC-42 (2)  ·  Lapatinib (2)  ·  Magnetic Resonance Imaging (2)  ·  Methylprednisolone (2)  ·  Prednisone (2)  ·  Sirolimus (2)

Sponsors

Massachusetts Eye and Ear Infirmary (6)  ·  Massachusetts General Hospital (6)  ·  Beijing Tiantan Hospital (5)  ·  NYU Langone Health (5)  ·  Assistance Publique - Hôpitaux de Paris (4)  ·  University Hospital, Strasbourg, France (4)  ·  University of North Carolina, Chapel Hill (4)  ·  Johns Hopkins University (3)  ·  Lund University (3)  ·  Medical University of Vienna (3)  ·  National Institute on Deafness and Other Communication Disorders (NIDCD) (3)  ·  University College, London (3)  ·  University Hospital Tuebingen (3)  ·  University of Alabama at Birmingham (3)  ·  University of Maryland, College Park (3)

Countries

United States (83)  ·  France (23)  ·  United Kingdom (11)  ·  China (10)  ·  Austria (5)  ·  Canada (5)  ·  Germany (5)  ·  Norway (4)  ·  Sweden (4)  ·  Denmark (3)  ·  Czechia (2)  ·  Egypt (2)  ·  Israel (2)  ·  Italy (2)  ·  Netherlands (2)

Top investigators

Ana-Maria Vranceanu, PhD (3)  ·  Keri J Heilman, PhD (3)  ·  Matthias A Karajannis, MD, MS (3)  ·  Aaron Tward, MD (2)  ·  D. Bradley Welling, MD, PhD (2)  ·  Fu Zhao (2)  ·  Matthew L Carlson, MD (2)  ·  Pinan Liu (2)  ·  Sandra Gordon-Salant, Ph.D. (2)  ·  Scott Plotkin, MD (2)  ·  Theodore Nicolaides, MD (2)  ·  Achim Klug, PhD (1)  ·  Alexander A Tarnutzer, MD (1)

Results publications

PMID 17917842, PMID 19574236, PMID 19645909, PMID 22027076, PMID 10449559, PMID 11587600, PMID 11710496, PMID 11981398, PMID 12925338, PMID 12943357, PMID 14724495, PMID 15269315, PMID 15354006, PMID 15519876, PMID 15979939, PMID 17141563, PMID 17438254, PMID 17562049, PMID 17905655, PMID 18607963, PMID 18769654, PMID 19464947, PMID 19645932, PMID 19931608, PMID 20517167, PMID 20541460, PMID 20592851, PMID 20592852, PMID 20647135, PMID 20649238, PMID 20709596, PMID 20802221, PMID 20851113, PMID 20968326, PMID 21110610, PMID 21586257, PMID 21993052, PMID 22434018, PMID 23123220, PMID 23333609, PMID 23337978, PMID 23573135, PMID 23673615, PMID 23862836, PMID 24604142, PMID 24904885, PMID 25698021, PMID 25745609, PMID 26055840, PMID 26237266

NIH funding

2017 (1), I01RX005059 (1), P01AG009524 (1), P01AG055365 (1), P30CA006973 (1), P30CA008748 (1), P30CA086862 (1), R01DC003196 (1), R01DC012593 (1), R01DC017425 (1), R01DC017924 (1), R44CA261240 (1), U01CA069856 (1), U01DC013778 (1)